Mallinckrodt and Terumo BCT Announce Positive Recommendations for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Treatment of Cutaneous T-Cell Lymphoma (CTCL) in Adults
– In a rare dual-review process, two independent advisory committees to the Australian Minister for Health recommend reimbursement based on a favorable clinical and cost-effectiveness comparison – STAINES-UPON-THAMES, United Kingdom and LAKEWOOD, Colorado, July 13, 2020 /PRNewswire/ -- Mallinckr...
Mallinckrodt and Terumo BCT Announce UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for the Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in Adults
SYDNEY, Nov. 1, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that UVADEX® (methoxsalen) has received regulatory approval inAustralia by th...
Mallinckrodt's INOmax™ (Nitric Oxide) Gas, for Inhalation, Approved in Australia for Pulmonary Hypertension in Adults in Conjunction with Cardiovascular Surgery
-- Expands approved indication in Australia to include use of INOmax for perioperative pulmonary hypertension in conjunction with cardiovascular surgery in neonates through adults -- SYDNEY, April 11, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical co...
Mallinckrodt Announces Extracorporeal Photopheresis (ECP) Research Collaboration Agreement With Transimmune AG
-- Collaboration with experts in photopheresis field expected to further enhance understanding of photopheresis' effect on immune modulation across a range of severe and critical conditions -- -- Agreement includes joint development activities for potential next-generation photopheresis system t...
Mallinckrodt Announces Interim Analysis Results for Therakos® Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease
-- Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol -- STAINES-UPON-THAMES, United Kingdom, Feb. 21, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceutical ...
Mallinckrodt Announces Interim Analysis Results for Therakos(R) Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease
-- Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol -- STAINES-UPON-THAMES, United Kingdom, Feb. 21, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceutical ...
